Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains ...

The distinction between sIBM and the other, mostly hereditary vacuolar myopathies, such as myofibrillar myopathies or hereditary inclusion body myopathy with mutations in the glucosamine (UDP-N ...

The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body ...

“They’re not going anywhere.” Krukow has inclusion body myositis, known as IBM, a degenerative disease that weakens muscles over time. He has been especially grateful that the Giants bought ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...

sIBM is a complex disorder, the underlying cause of which is unclear. The observation that the intact muscle fibers are invaded by T lymphocytes, whereas the vacuolated fibers lack T-cell ...